Results 21 to 30 of about 162,220 (306)

Occupational interstitial lung diseases

Journal of Internal Medicine, 2023
AbstractMillions of workers are exposed to substances known to cause occupational interstitial lung diseases (ILDs), particularly in developing countries. However, the burden of the disease is likely to be underestimated due to under‐recognition, under‐reporting or both.
Spagnolo, Paolo, Ryerson, Christopher J, Guler, Sabina, Feary, Johanna, Churg, Andrew, Fontenot, Andrew P, Piciucchi, Sara, Udwadia, Zarir, Corte, Tamera J, Wuyts, Wim A, Johannson, Kerri A, Cottin, Vincent   +11 more
openaire   +4 more sources

Interstitial Lung Disease in the Elderly [PDF]

Chest, 2017
Despite the relationship between idiopathic pulmonary fibrosis (IPF) and advancing age, little is known about the epidemiology of interstitial lung disease (ILD) in the elderly. We describe the diagnoses, clinical characteristics, and outcomes of patients who were elderly at the time of ILD diagnosis.Among subjects from a prospective cohort study of ...
Matthew J. Triano, Matthew Chadwick, Rupal J. Shah, Charuhas Deshpande, Milton D. Rossman, Karen C. Patterson, Leslie A. Litzky, Maryl Kreider, Mary K. Porteous, Wallace T. Miller, Jason D. Christie, Carly A. D’Errico   +11 more
openaire   +3 more sources

Prognostic factors in chronic hypersensitivity pneumonitis

European Respiratory Review, 2020
Hypersensitivity pneumonitis (HP) is an immunologically mediated lung disease resulting from exposure to inhaled environmental antigens. Prognosis is variable, with a subset of patients developing progressive fibrosis leading to respiratory failure and ...
Andrew W. Creamer, Shaney L. Barratt
doaj   +1 more source

Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity

Revista Portuguesa de Pneumologia (English Edition), 2017
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years.
E.B. Boerner, U. Costabel, T.E. Wessendorf, D. Theegarten, F. Bonella   +4 more
doaj   +1 more source

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

Frontiers in Medicine, 2020
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline.
Sachin Chaudhary, Bhupinder Natt, Christian Bime, Kenneth S. Knox, Kenneth S. Knox, Marilyn K. Glassberg   +5 more
doaj   +1 more source

Immune mechanisms in fibrotic pulmonary sarcoidosis

European Respiratory Review, 2022
Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area.
Praveen Weeratunga, David R. Moller, Ling-Pei Ho   +2 more
doaj   +1 more source

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults

BMC Pulmonary Medicine, 2019
Background Diffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT).
Anna Stainer, Alex Rice, Anand Devaraj, Joseph Luke Barnett, Jacqueline Donovan, Maria Kokosi, Andrew Gordon Nicholson, Tom Cairns, Athol Umfrey Wells, Elisabetta Augusta Renzoni   +9 more
doaj   +1 more source

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study

BMJ Open Respiratory Research, 2023
Background Opportunities for home-monitoring are increasing exponentially. Home- spirometry is reproducible and reliable in interstitial lung disease (ILD), yet patients’ experiences are not reported.
Sarah Lines, Michael Gibbons, Rebecca Shuttleworth, Anne-Marie Russell, Graham Brown, Anna Duckworth, Alex Berry, Jessica Mandizha, Joseph W Lanario, Ana Paiva, Victoria Elworthy, Veena Muraleedharan, Ana Jorge Da Ponte, Howard Almond, Carole Bond, Maureen Cosby, Joanne Dallas, Marium Naqvi, Adam David Russell, Christopher J Scotton   +19 more
doaj   +1 more source

Recent advances in the treatment of systemic sclerosis associated interstitial lung disease

Frontiers in Medicine, 2023
Connective tissue diseases (CTDs) are a heterogenous group of systemic inflammatory disorders. The development of connective tissue disease-associated interstitial lung disease (CTD-ILD) is a key complication associated with significant morbidity and ...
Antoniya Kamenova, Argyris Tzouvelekis, George A. Margaritopoulos   +2 more
doaj   +1 more source

Pharmacogenetics and interstitial lung disease [PDF]

Current Opinion in Pulmonary Medicine, 2016
Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific
Oldham, Justin M, Noth, Imre, Martinez, Fernando J   +2 more
openaire   +5 more sources